Antigenic mimicry of the HIV envelope by AIDS-associated pathogens

AIDS

Volumn 22, Issue 16, 2008, Pages 2214-2217

  Dunlop, D Cameron ^a   Ulrich, Alexander ^b   Appelmelk, Ben J ^c   Burton, Dennis R ^d   Dwek, Raymond A ^a   Zitzmann, Nicole ^a   Scanlan, Christopher N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; FRUCTOSE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MANNAN; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY 2G12; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY SPECIFICITY; ARTICLE; CANDIDA ALBICANS; CANDIDA TROPICALIS; CROSS REACTION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL TOLERANCE; MOLECULAR INTERACTION; MOLECULAR MIMICRY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; SACCHAROMYCES CEREVISIAE;

ANTIBODIES, MONOCLONAL; ANTIGENS, FUNGAL; CANDIDA; CROSS REACTIONS; HIV ENVELOPE PROTEIN GP120; HUMANS; MOLECULAR MIMICRY;

EID: 55249109998     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328314b5df     Document Type: Article

References (31)

1. Scanlan CN, Offer J, Zitzmann N, Dwek RA. Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 2007; 446:1038-1045.
2. Kunert R, Ruker F, Katinger H. Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal anti-bodies 2G12 and 2F5. AIDS Res Hum Retroviruses 1998; 14:1115-1128.
3. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002; 76:7293-7305.
4. Katinger H. Human monoclonal antibodies for passive immunotherapy of HIV-1. Antibiot Chemother 1994; 46:25-37.
5. Calarese DA, Lee HK, Huang CY, Best MD, Astronomo RD, Stanfield RL, et al. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci USA 2005; 102:13372-13377.
6. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003; 300:2065-2071.
7. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, et al. The broadly neutralizing antihuman immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J Virol 2002; 76:7306-7321.
8. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996; 70:1100-1108.
9. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6:207-210.
10. Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006; 24:739-769.
11. Lee HK, Scanlan CN, Huang CY, Chang AY, Calarese DA, Dwek RA, et al. Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody. Angew Chem Int Ed Engl 2004; 43:1000-1003.
12. Blixt O, Head S, Mondala T, Scanlan C, Huflejt ME, Alvarez R, et al. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci USA 2004; 101:17033- 17038.
13. Astronomo RD, Lee HK, Scanlan CN, Pantophlet R, Huang CY, Wilson IA, et al. A glycoconjugate antigen, based on the recognition motif of a broadly-neutralising HIV antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the 'self' glycans of gp120. J Virol 2008; 82:6359-6368.
14. Scanlan CN, Ritchie GE, Baruah K, Crispin M, Harvey DJ, Singer BB, et al. Inhibition of mammalian glycan biosynthesis produces nonself antigens for a broadly neutralising, HIV-1 specific antibody. J Mol Biol 2007; 372:16-22.
15. Luallen RJ, Lin J, Fu H, Cai KK, Agrawal C, Mboudjeka I, et al. An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing HIV-1 antibody 2G12 and elicits mannose-specific, gp120 binding antibodies. J Virol 2008; 82:6447-6457.
16. Ni J, Song H, Wang Y, Stamatos NM, Wang LX. Toward a carbohydrate-based HIV-1 vaccine: synthesis and immunological studies of oligomannose-containing glycoconjugates. Bioconjug Chem 2006; 17:493-500.
17. Wang LX. Toward oligosaccharide- and glycopeptide-based HIV vaccines. Curr Opin Drug Discov Devel 2006; 9:194-206.
18. Wang LX, Ni J, Singh S, Li H. Binding of high-mannose-type oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design. Chem Biol 2004; 11:127-134.
19. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, et al. Comprehensive cross-clade neutralization analysis of a panel of antihuman immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78:13232-13252.
20. Zhang M, Gaschen B, Blay W, Foley B, Haigwood N, Kuiken C, Korber B. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 2004; 14:1229-1246.
21. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11:615-622.
22. Fidel PL Jr. Immunity to Candida. Oral Dis 2002; 8 (Suppl 2): 69-75.
23. Shan M, Klasse PJ, Banerjee K, Dey AK, Iyer SP, Dionisio R, et al. HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog 2007; 3:e169.
24. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol 2002; 2:706-713.
25. Vcelar B, Stiegler G, Wolf HM, Muntean W, Leschnik B, Mehandru S, et al. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS 2007; 21:2161-2170.
26. Scherer EM, Zwick MB, Teyton L, Burton DR. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 2007; 21:2131-2139.
27. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308:1906-1908.
28. Montero M, van Houten NE, Wang X, Scott JK. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 2008; 72:54-84; table of contents.
29. Muller WE, Bachmann M, Weiler BE, Schröder HC, Uhlenbruck G, Shinoda T, et al. Antibodies against defined carbohydrate structures of Candida albicans protect H9 cells against infection with human immunodeficiency virus-1 in vitro. J Acquir Immune Defic Syndr 1991; 4:694-703.
30. Muller WE, Schroder HC, Reuter P, Maidhof A, Uhlenbruck G, Winkler I. Polyclonal antibodies to mannan from yeast also recognize the carbohydrate structure of gp120 of the AIDS virus: an approach to raise neutralizing antibodies to HIV-1 infection in vitro. AIDS 1990; 4:159-162.
31. Tomiyama T, Lake D, Masuho Y, Hersh EM. Recognition of human immunodeficiency virus glycoproteins by natural anticarbohydrate antibodies in human serum. Biochem Biophys Res Commun 1991; 177:279-285.